Skip to main content
Smart Investors Daily
Bruker Corporation logo

NASDAQ · BRKR

Bruker Corporation

Healthcare · Medical - Devices

$62.10

Down-$1.16 (-1.83%)

Updated Nov 20, 2026, 9:35 AM

SID Score

7.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
7.04B
P/E ratio
-355.31
Dividend yield
0.32%
52-week range
$32.37 – $68.98
Volume
1.85M
Avg. volume
3.15M

Price performance · BRKR

BRKR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

BRKR closed at $62.10 after 21 trading sessions, up 8.36% for the selected period.

Last close
$62.10
Period change
+8.36%
Period low
$55.69
Period high
$66.54
Daily close
View OHLC price history
BRKR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$63.82$65.82$62.04$62.101.85M
Nov 18, 2026$61.09$64.61$61.00$63.261.73M
Nov 17, 2026$60.38$62.22$60.025$61.361.88M
Nov 16, 2026$60.52$61.805$59.50$60.622.65M
Nov 13, 2026$60.36$61.94$59.13$61.592.02M
Nov 12, 2026$60.46$61.40$58.675$60.331.51M
Nov 11, 2026$63.68$64.28$61.96$62.412.47M
Nov 10, 2026$65.51$66.51$62.13$62.242.88M
Nov 9, 2026$62.30$67.05$61.695$66.542.86M
Nov 6, 2026$59.00$61.68$58.46$61.312.01M
Nov 5, 2026$61.94$62.33$57.86$58.063.26M
Nov 4, 2026$65.39$68.98$59.125$63.797.41M
Nov 3, 2026$57.07$59.38$55.80$56.504.34M
Nov 2, 2026$57.07$57.195$55.15$55.691.89M
Oct 30, 2026$60.00$60.17$56.0034$57.071.92M
Oct 29, 2026$61.18$62.54$61.00$62.001.5M
Oct 28, 2026$60.66$63.39$60.55$62.002.99M
Oct 27, 2026$58.43$61.00$57.745$60.742.38M
Oct 26, 2026$57.79$58.30$57.275$58.232.33M
Oct 23, 2026$56.93$57.7785$55.32$57.591.22M
Oct 22, 2026$59.11$60.665$55.52$57.312.37M

Latest BRKR news

The latest Smart Investors Daily articles mentioning BRKR.

BRKR research

Overview

Company profile and research snapshot.

Company profile

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$49.71
Implied upside
—
Analysts
20
BRKR recent ratings
DateFirmRatingTarget
Nov 5, 2026Leerink PartnersOutperform—
Nov 5, 2026CitigroupNeutral—
Oct 14, 2026JP MorganNeutral—
Oct 13, 2026TD CowenHold—
Oct 7, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

The 5 most interesting analyst questions from Bruker’s Q3 2026 earnings call

Bruker’s third quarter drew a positive response from the market, as the company delivered a notable step-up in profitability despite only modest topline growth. Management attributed the margin expansion to the combination of disciplined cost-saving actions and a favorable product mix, particularly in NMR and optical microscopy. CEO Frank Laukien emphasized that “our focus on cost discipline and execution” led to the significant improvement in non-GAAP earnings per share and operating margins. T

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.